Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins

被引：29

作者：

Zeng, Meiqi ^{[1
]}

Zheng, Manyin ^{[1
]}

Lu, Desheng ^{[1
]}

Wang, Jun ^{[1
]}

Jiang, Wenqi ^{[1
,2
,3
,4
]}

Sha, Ou ^{[1
]}

机构：

[1] Shenzhen Univ, Hlth Sci Ctr, Sch Med, Shenzhen 518060, Guangdong, Peoples R China

[2] Shenzhen Univ, Sch Med, Shenzhen 518060, Guangdong, Peoples R China

[3] State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China

[4] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China

来源：

CHINESE JOURNAL OF CANCER | 2015年 / 34卷

关键词：

Ribosome-inactivating protein (RIP); Anti-tumor; Apoptosis; Cancer; CELLS IN-VITRO; NASOPHARYNGEAL CARCINOMA-CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; RGEL/BLYS FUSION TOXIN; CANCER-CELLS; ALPHA-SARCIN; ASPERGILLUS-GIGANTEUS; ANTI-CD33; IMMUNOTOXIN; ANTICANCER ACTIVITY; SIGNALING PATHWAY;

D O I：

10.1186/s40880-015-0030-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ribosome-inactivating proteins (RIPs) belong to a family of enzymes that attack eukaryotic ribosomes and potently inhibit cellular protein synthesis. RIPs possess several biomedical properties, including anti-viral and anti-tumor activities. Multiple RIPs are known to inhibit tumor cell proliferation through inducing apoptosis in a variety of cancers, such as breast cancer, leukemia/lymphoma, and hepatoma. This review focuses on the anti-tumor activities of RIPs and their apoptotic effects through three closely related pathways: mitochondrial, death receptor, and endoplasmic reticulum pathways.

引用

页数：10

共 50 条

[31] Transcriptional network inference and master regulator analysis of the response to ribosome-inactivating proteins in leukemia cells
Mercatelli, Daniele
Bortolotti, Massimo
Giorgi, Federico M.
TOXICOLOGY, 2020, 441
[32] In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins
Bolognesi, A
Polito, L
Tazzari, PL
Lemoli, RM
Lubelli, C
Fogli, M
Boon, L
De Boer, M
Stirpe, F
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (02) : 351 - 361
[33] Non-toxic type 2 ribosome-inactivating proteins (RIPs) from Sambucus:: Occurrence, cellular and molecular activities and potential uses
Girbes, T
Ferreras, JM
Arias, FJ
Muñoz, R
Iglesias, R
Jimenez, P
Rojo, MA
Arias, Y
Perez, Y
Benitez, J
Sanchez, D
Gayoso, MJ
CELLULAR AND MOLECULAR BIOLOGY, 2003, 49 (04) : 537 - 545
[34] The ribosome-inactivating proteins MAP30 and Momordin inhibit SARS-CoV-2
Watts, Norman
Eren, Elif H.
Palmer, Ira
Huang, Paul T.
Huang, Philip Lin
Shoemaker, Robert
Lee-Huang, Sylvia
Wingfield, Paul
PLOS ONE, 2023, 18 (06):
[35] Advances in research on the anti-tumor mechanism of Astragalus polysaccharides
Yang, Qian
Meng, Dandan
Zhang, Qinyuan
Wang, Jin
FRONTIERS IN ONCOLOGY, 2024, 14
[36] Production of Anti-Cancer Immunotoxins in Algae: Ribosome Inactivating Proteins as Fusion Partners
Tran, Miller
Henry, Ryan E.
Siefker, David
Van, Christina
Newkirk, Greg
Kim, Julie
Bui, Jack
Mayfield, Stephen P.
BIOTECHNOLOGY AND BIOENGINEERING, 2013, 110 (11) : 2826 - 2835
[37] Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells
Horrix, C.
Raviv, Z.
Flescher, E.
Voss, C.
Berger, M. R.
CELLULAR AND MOLECULAR LIFE SCIENCES, 2011, 68 (07) : 1269 - 1281
[38] PRECLINICAL EVALUATION OF THE RIBOSOME-INACTIVATING PROTEINS PAP-1, PAP-S AND RTA IN MICE
BENIGNI, F
CANEVARI, S
GADINA, M
ADOBATI, E
FERRERI, AJM
DICELLE, EF
COLNAGHI, MI
COLNAGHI, MI
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1995, 17 (10): : 829 - &
[39] Pharmacological effect and mechanism of orlistat in anti-tumor therapy A review
Hao, Xiaoqing
Zhu, Xiaodi
Tian, Huiqun
Lai, Guanxi
Zhang, Wei
Zhou, Honghao
Liu, Song
MEDICINE, 2023, 102 (36) : E34671
[40] Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative
Yi, EY
Jeong, EJ
Song, HS
Lee, MS
Kang, DW
Joo, JH
Kwon, HS
Lee, SH
Park, SK
Chung, SG
Cho, EH
Kim, YJ
INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (02) : 365 - 372

← 1 2 3 4 5 →